Literature DB >> 34295037

Evaluation of possible prophylactic and therapeutic effect of mefloquine on experimental cryptosporidiosis in immunocompromised mice.

Eman S El-Wakil1, Amal E Salem2, Asmaa M F Al-Ghandour3.   

Abstract

Cryptosporidiosis is an imperative global health concern. Unfortunately, Nitazoxanide (NTZ) (the nowadays drug of choice) is not effective in treatment of immunocompromised patients. We aimed to assess the possible anti-cryptosporidial prophylactic and therapeutic effects of Mefloquine (MQ) on infected immunosuppressed murine models. Mice were divided into five groups; GI: received Mefloquine (400 mg/kg/day), GII: received NTZ (100 mg/kg/bid), GIII: received a combination, half dose regimen of both drugs, GIV: infected untreated and GV: non-infected untreated. Each treated group was divided into three subgroups; Ga prophylaxis (PX), thereafter infection, Gb first and Gc second treatment doses. Assessment was done by parasitological, histopathological and serological techniques. A significant oocyst clearance was detected in all prophylactically treated groups. GIa showed 77% reduction of the mean oocyst count in stool while GIb and GIIIc showed100% oocyst clearance. Histopathologically, the ileocecal sections from GIV showed loss of brush borders with marked villous atrophy. GIa induced a moderate improvement of those pathological changes. Moreover, the villi in GIb and GIIIc retained their normal appearance with minimal inflammatory cells. Serum interferon gamma levels showed highly significant increases in GI&GIII compared to GIV while a non-significant increase was observed in GIIa only. On the contrary, serum interleukin-17 levels showed a highly significant down-regulation in all treated groups in comparison to GIV. This study proved a marvelous effect of MQ-PX on cryptosporidiosis in immunosuppressed mice and thus it could be introduced as one of the most promising re-purposed prophylactic and therapeutic anti-cryptosporidial agents. © Indian Society for Parasitology 2020.

Entities:  

Keywords:  Cryptosporidium; Interferon gamma; Interleukin-17; Mefloquine; Nitazoxanide; Prophylaxis

Year:  2020        PMID: 34295037      PMCID: PMC8254681          DOI: 10.1007/s12639-020-01315-4

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  92 in total

Review 1.  The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases.

Authors:  Rajita Pappu; Vladimir Ramirez-Carrozzi; Arivazhagan Sambandam
Journal:  Immunology       Date:  2011-07-04       Impact factor: 7.397

2.  The Treg/Th17 imbalance in Toxoplasma gondii-infected pregnant mice.

Authors:  Haixia Zhang; Xuemei Hu; Xianbing Liu; Ruijin Zhang; Qiang Fu; Xiaoyan Xu
Journal:  Am J Reprod Immunol       Date:  2011-09-19       Impact factor: 3.886

Review 3.  Mefloquine for malaria chemoprophylaxis 1992-1998: a review.

Authors:  P Schlagenhauf
Journal:  J Travel Med       Date:  1999-06       Impact factor: 8.490

4.  Cryptosporidium infection in major histocompatibility complex congeneic strains of mice: variation in susceptibility and the role of T-cell cytokine responses.

Authors:  M H Davami; G J Bancroft; V McDonald
Journal:  Parasitol Res       Date:  1997       Impact factor: 2.289

5.  IL-17 neutralization significantly ameliorates hepatic granulomatous inflammation and liver damage in Schistosoma japonicum infected mice.

Authors:  Yuxia Zhang; Liuxi Chen; Wenda Gao; Xin Hou; Yuqing Gu; Li Gui; Dake Huang; Miao Liu; Cuiping Ren; Siying Wang; Jijia Shen
Journal:  Eur J Immunol       Date:  2012-06       Impact factor: 5.532

6.  Requirements for CD4+ cells and gamma interferon in resolution of established Cryptosporidium parvum infection in mice.

Authors:  W Chen; J A Harp; A G Harmsen
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

7.  Dynamics of Th17 associating cytokines in Cryptosporidium parvum-infected mice.

Authors:  G H Zhao; Y Q Fang; U Ryan; Y X Guo; F Wu; S Z Du; D K Chen; Q Lin
Journal:  Parasitol Res       Date:  2015-11-23       Impact factor: 2.289

8.  Cryptosporidium parvum infection in experimentally infected mice: infection dynamics and effect of immunosuppression.

Authors:  R Tarazona; D A Blewett; M D Carmona
Journal:  Folia Parasitol (Praha)       Date:  1998       Impact factor: 2.122

Review 9.  Implications of acquired environmental enteric dysfunction for growth and stunting in infants and children living in low- and middle-income countries.

Authors:  Gerald T Keusch; Irwin H Rosenberg; Donna M Denno; Christopher Duggan; Richard L Guerrant; James V Lavery; Philip I Tarr; Honorine D Ward; Robert E Black; James P Nataro; Edward T Ryan; Zulfiqar A Bhutta; Hoosen Coovadia; Aldo Lima; Balakrishnan Ramakrishna; Anita K M Zaidi; Deborah C Hay Burgess; Thomas Brewer
Journal:  Food Nutr Bull       Date:  2013-09       Impact factor: 2.069

10.  Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery.

Authors:  J K Griffiths; R Balakrishnan; G Widmer; S Tzipori
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

View more
  1 in total

1.  Nitazoxanide, Ivermectin, and Artemether effects against cryptosporidiosis in diabetic mice: parasitological, histopathological, and chemical studies.

Authors:  Ayman M El-Ashkar; Soheir Mahmoud; Hoda Sabry; Nevine Guirguis; Wafaa El Komi; Eman Ali; Tarek Abu Shousha; Hagar F Abdelmksoud
Journal:  J Parasit Dis       Date:  2022-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.